Ningbo Menovo Pharmaceutical Co., Ltd.
Symbol: 603538.SS
SHH
14.58
CNYMarknadspris idag
-165.8310
P/E-tal
-26.5330
PEG-kvot
3.09B
MRK Aktiekapital
- 0.01%
DIV Avkastning
{{företagets_namn}} (603538-SS) Finansiella rapporter
Balansräkning
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 724.7 | 1009.3 | 793.2 | |||||||||||||
balance-sheet.row.short-term-investments | 0 | 268.6 | 217.4 | 371.4 | |||||||||||||
balance-sheet.row.net-receivables | 0 | 320.7 | 231.5 | 266.2 | |||||||||||||
balance-sheet.row.inventory | 0 | 612.6 | 594.4 | 579.7 | |||||||||||||
balance-sheet.row.other-current-assets | 0 | 50.3 | 59.2 | 63.4 | |||||||||||||
balance-sheet.row.total-current-assets | 0 | 1759.4 | 1894.4 | 1702.4 | |||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 1900.3 | 1801.9 | 1614.7 | |||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 22.7 | |||||||||||||
balance-sheet.row.intangible-assets | 0 | 206.2 | 172.5 | 201.7 | |||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 206.2 | 172.5 | 224.4 | |||||||||||||
balance-sheet.row.long-term-investments | 0 | 315.3 | 82.7 | -51.8 | |||||||||||||
balance-sheet.row.tax-assets | 0 | 42.7 | 123.1 | 33.3 | |||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 199.6 | 344.8 | 478.5 | |||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 2664.1 | 2525.1 | 2299.1 | |||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-assets | 0 | 4423.5 | 4419.5 | 4001.5 | |||||||||||||
balance-sheet.row.account-payables | 0 | 553.7 | 499.3 | 389.1 | |||||||||||||
balance-sheet.row.short-term-debt | 0 | 542.8 | 497 | 505 | |||||||||||||
balance-sheet.row.tax-payables | 0 | 25.5 | 72.1 | 34.6 | |||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 759.6 | 705.6 | 755.3 | |||||||||||||
Deferred Revenue Non Current | 0 | 81.5 | 70.6 | 48.7 | |||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||
balance-sheet.row.other-current-liab | 0 | 2 | 171 | 3.9 | |||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 859.6 | 884 | 876.2 | |||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 15.7 | 30.3 | 28 | |||||||||||||
balance-sheet.row.total-liab | 0 | 2237.8 | 2246.2 | 2023 | |||||||||||||
balance-sheet.row.preferred-stock | 0 | 36.3 | 0 | 0 | |||||||||||||
balance-sheet.row.common-stock | 0 | 213.4 | 213.4 | 151.3 | |||||||||||||
balance-sheet.row.retained-earnings | 0 | 1210.6 | 1234.3 | 937.4 | |||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 75.6 | 101.4 | 77.6 | |||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 560.4 | 535.9 | 585.2 | |||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 2096.3 | 2085 | 1751.5 | |||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 4423.5 | 4419.5 | 4001.5 | |||||||||||||
balance-sheet.row.minority-interest | 0 | 89.4 | 88.3 | 227 | |||||||||||||
balance-sheet.row.total-equity | 0 | 2185.7 | 2173.2 | 1978.5 | |||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||||
Total Investments | 0 | 315.3 | 300.1 | 319.6 | |||||||||||||
balance-sheet.row.total-debt | 0 | 1302.5 | 1202.6 | 1260.4 | |||||||||||||
balance-sheet.row.net-debt | 0 | 846.4 | 410.7 | 838.6 |
Kassaflödesanalys
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 367.6 | 158.1 | 173.1 | ||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 101.8 | 98.9 | 85 | ||||||||||||
cash-flows.row.deferred-income-tax | 0 | -40.2 | -21 | 18.4 | ||||||||||||
cash-flows.row.stock-based-compensation | 0 | 24.7 | 5.3 | 10.9 | ||||||||||||
cash-flows.row.change-in-working-capital | 0 | -85.4 | -62.2 | -2.8 | ||||||||||||
cash-flows.row.account-receivables | 0 | -213.6 | -50.9 | -28.2 | ||||||||||||
cash-flows.row.inventory | 0 | -183 | -124.7 | -83 | ||||||||||||
cash-flows.row.account-payables | 0 | 351.4 | 134.4 | 63.3 | ||||||||||||
cash-flows.row.other-working-capital | 0 | -40.2 | -21 | 45.1 | ||||||||||||
cash-flows.row.other-non-cash-items | 0 | -91.4 | 41.5 | -32.9 | ||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -571.6 | -529.9 | -311.7 | ||||||||||||
cash-flows.row.acquisitions-net | 0 | 487.9 | -47.1 | 0.5 | ||||||||||||
cash-flows.row.purchases-of-investments | 0 | -713.9 | -1640.5 | -865 | ||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 902.5 | 1562.2 | 693.5 | ||||||||||||
cash-flows.row.other-investing-activites | 0 | -54.6 | 52 | 3.8 | ||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 50.3 | -603.3 | -479 | ||||||||||||
cash-flows.row.debt-repayment | 0 | -749.5 | -788.1 | -802.5 | ||||||||||||
cash-flows.row.common-stock-issued | 0 | 0.1 | 0.2 | 0.5 | ||||||||||||
cash-flows.row.common-stock-repurchased | 0 | -0.1 | -0.2 | -0.5 | ||||||||||||
cash-flows.row.dividends-paid | 0 | -50 | -13.8 | -41 | ||||||||||||
cash-flows.row.other-financing-activites | 0 | 621.1 | 1385.1 | 981.9 | ||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -178.5 | 583.1 | 138.4 | ||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 14.6 | -2.3 | -2 | ||||||||||||
cash-flows.row.net-change-in-cash | 0 | 163.4 | 198.2 | -91 | ||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 537 | 373.6 | 174.5 | ||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 373.6 | 175.4 | 265.5 | ||||||||||||
cash-flows.row.operating-cash-flow | 0 | 277 | 220.6 | 251.6 | ||||||||||||
cash-flows.row.capital-expenditure | 0 | -571.6 | -529.9 | -311.7 | ||||||||||||
cash-flows.row.free-cash-flow | 0 | -294.7 | -309.3 | -60.1 |
Resultaträkning rad
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 1216.5 | 1457 | 1258.1 | |||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 840.9 | 872.8 | 788.9 | |||||||||||||
income-statement-row.row.gross-profit | 0 | 375.6 | 584.2 | 469.2 | |||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-expenses | 0 | -10.8 | 116.4 | 110.8 | |||||||||||||
income-statement-row.row.operating-expenses | 0 | 291.2 | 341.4 | 281 | |||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 1132.1 | 1214.2 | 1069.9 | |||||||||||||
income-statement-row.row.interest-income | 0 | 5.5 | 5.7 | 2.2 | |||||||||||||
income-statement-row.row.interest-expense | 0 | 29.1 | 27.4 | 27.2 | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -76.4 | -21.2 | -7.6 | |||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-operating-expenses | 0 | -10.8 | 116.4 | 110.8 | |||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -76.4 | -21.2 | -7.6 | |||||||||||||
income-statement-row.row.interest-expense | 0 | 29.1 | 27.4 | 27.2 | |||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 118.5 | 128.3 | 124.1 | |||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||||
income-statement-row.row.operating-income | 0 | 18.7 | 405.3 | 187.9 | |||||||||||||
income-statement-row.row.income-before-tax | 0 | 8 | 384.2 | 180.3 | |||||||||||||
income-statement-row.row.income-tax-expense | 0 | -8.2 | 16.5 | 22.2 | |||||||||||||
income-statement-row.row.net-income | 0 | 11.6 | 338.9 | 142.5 |
Ofta ställda frågor
Vad är Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS) totala tillgångar?
Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS) totala tillgångar är 4423515920.000.
Vad är företagets årliga omsättning?
Den årliga intäkten är N/A.
Vad är företagets vinstmarginal?
Företagets vinstmarginal är 0.319.
Vad är företagets fria kassaflöde?
Fritt kassaflöde är -0.853.
Vad är företagets nettovinstmarginal?
Nettovinstmarginalen är -0.014.
Vad är företagets totala intäkter?
Totala intäkter är -0.013.
Vad är Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS) nettovinst (nettoinkomst)?
Nettovinst (nettoinkomst) är 11585592.000.
Vad är företagets totala skuldsättning?
Den totala skulden är 1302458461.000.
Vad är rörelsens kostnader?
Rörelsens kostnader är 291175048.000.
Vad är företagets kassaflöde?
Företagets kassa är 0.000.